JiangXi Tianxin Pharmaceutical Past Earnings Performance
Past criteria checks 1/6
JiangXi Tianxin Pharmaceutical's earnings have been declining at an average annual rate of -13.4%, while the Personal Products industry saw earnings growing at 9.8% annually. Revenues have been declining at an average rate of 21% per year. JiangXi Tianxin Pharmaceutical's return on equity is 11.8%, and it has net margins of 28.6%.
Key information
-13.4%
Earnings growth rate
-16.4%
EPS growth rate
| Personal Products Industry Growth | 7.8% |
| Revenue growth rate | -21.0% |
| Return on equity | 11.8% |
| Net Margin | 28.6% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How JiangXi Tianxin Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 1,798 | 515 | 162 | 119 |
| 31 Dec 23 | 1,882 | 476 | 169 | 112 |
| 30 Sep 23 | 2,042 | 484 | 170 | 91 |
| 30 Jun 23 | 2,184 | 551 | 170 | 91 |
| 31 Mar 23 | 2,277 | 553 | 172 | 90 |
| 31 Dec 22 | 2,305 | 622 | 171 | 89 |
| 30 Sep 22 | 2,378 | 713 | 160 | 78 |
| 30 Jun 22 | 2,496 | 725 | 157 | 72 |
| 31 Mar 22 | 2,488 | 716 | 149 | 62 |
| 31 Dec 21 | 2,522 | 744 | 147 | 59 |
| 31 Dec 20 | 2,304 | 887 | 129 | 49 |
| 31 Dec 19 | 2,025 | 728 | 146 | 48 |
| 31 Dec 18 | 2,578 | 1,098 | 257 | 44 |
Quality Earnings: 603235 has a high level of non-cash earnings.
Growing Profit Margin: 603235's current net profit margins (28.6%) are higher than last year (24.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 603235's earnings have declined by 13.4% per year over the past 5 years.
Accelerating Growth: 603235's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 603235 had negative earnings growth (-6.8%) over the past year, making it difficult to compare to the Personal Products industry average (-0.2%).
Return on Equity
High ROE: 603235's Return on Equity (11.8%) is considered low.